There is some risk of more frequent/severe infections when on anti-TNF for UC patients. Strangely not for CD.
Anti-integrin (e.g., Entyevo type) did not have this risk.
http://journals.lww.com/ibdjournal/Abstract/publishahead/Risk_for_Overall_Infection_with_Anti_TNF_and.98632.aspx said...
Conclusions: Anti-tumor necrosis factor therapy but not anti-integrin therapy is associated with a greater infection risk than placebo in treating UC. Neither class of therapy is associated with increased infection risk over placebo in treating CD.
I guess given the choice, I would start with Entyevo and skip the anti-TNF drugs.